Validating plasminogen activator inhibitor‐1 as a poor prognostic factor in sepsis

• Published in: Acute medicine & surgery 2020-01, Vol.7 (1), p.e581-n/a
• Main Authors: Hoshino, Kota, Nakashio, Maiko, Maruyama, Junichi, Irie, Yuhei, Kawano, Yasumasa, Ishikura, Hiroyasu
• Format: Article
• Language: English
• Subjects: Biomarkers; Blood pressure; Catecholamines; Disseminated intravascular coagulation; Glasgow Coma Scale; Infections; Inflammation; Liver cirrhosis; Medical prognosis; Mortality; Multiple organ dysfunction syndrome; organ failure; Original; Patients; plasminogen activator inhibitor; Proteins; Sepsis; Ventilators
• ISSN: 2052-8817; 2052-8817
• DOI: 10.1002/ams2.581

Our previous study suggested that plasminogen activator inhibitor‐1 (PAI‐1) levels of ≥83 ng/mL were associated with poor outcomes in patients with sepsis. The results indicate that high PAI‐1 levels (≥83 ng/mL) were associated with increased risks of coagulopathy, organ failure, and mortality. Patients with sepsis and PAI‐1 levels of ≥83 ng/mL tended to develop disseminated intravascular coagulation within 1 week after the sepsis diagnosis. Aim Our previous report indicated that plasminogen activator inhibitor‐1 (PAI‐1) levels of ≥83 ng/mL in patients with sepsis tended to be associated with disseminated intravascular coagulation (DIC), suppressed fibrinolysis, multiple organ dysfunction, and mortality. Therefore, the present study aimed to validate whether 83 ng/mL was a useful cut‐off value for using PAI‐1 levels to predict a poor prognosis in sepsis. Methods Patients with sepsis were included in this single‐center retrospective study. The patients were classified as having high or low PAI‐1 values (